What Are the Symptoms of PML in Tysabri Patients?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specialized Risk Assessment

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is vital. The medical community has long recognized that while biologic therapies offer significant benefits, they also require vigilant safety monitoring. This page outlines the specific symptoms to track and what to discuss with your healthcare provider.

Clinical and Pharmacological Context of Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease when other treatments are not appropriate. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging (MRI showing characteristic white matter lesions), detection of JC virus DNA in cerebrospinal fluid, and sometimes brain biopsy. Early recognition is critical because prompt intervention may improve outcomes, though prognosis remains poor. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in MS but also impairs immune surveillance, allowing JC virus reactivation. The drug's labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 MS patients treated for a median of 120 weeks (both also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and urinary tract infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways and Risk Factors for PML

The primary mechanism linking Tysabri to PML is the drug's inhibition of lymphocyte trafficking across the blood-brain barrier. This reduces immune surveillance in the brain, allowing JC virus, which is latent in many individuals, to reactivate and cause lytic infection of oligodendrocytes. Three established risk factors increase PML risk: presence of anti-JCV antibodies (indicating prior JC virus exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information includes a boxed warning that clearly states Tysabri increases PML risk and that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also mandates monitoring and immediate withholding of Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is only available through a restricted distribution program called TOUCH, which aims to ensure informed prescribing and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients and clinicians may not fully appreciate the magnitude of risk, particularly in the context of long-term therapy.

Legal Considerations and Lawsuit Settlement Criteria

Patients who develop PML after Tysabri treatment may consider legal action if they believe warnings were inadequate or if risk factors were not properly assessed. Key considerations include whether healthcare providers discussed the three known risk factors (anti-JCV antibody status, treatment duration, prior immunosuppressant use) and whether monitoring protocols were followed. The boxed warning explicitly states that these factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Legal claims may focus on failure to warn, failure to monitor, or failure to discontinue therapy when PML was suspected. The TOUCH program's requirements for patient education and periodic monitoring may also be relevant. PML can occur at any time during Tysabri treatment, but risk increases with longer exposure. In clinical trials, PML occurred after a median of 120 weeks in MS patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling notes that longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Symptoms may develop insidiously, and diagnosis can be delayed, worsening outcomes. Prompt recognition and withholding of Tysabri are critical, but even with early intervention, PML often leads to severe disability or death.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of reducing immune surveillance in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the known risk factors for developing PML while on Tysabri?

Three established risk factors include: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal criteria might be considered in a Tysabri PML lawsuit?

Legal claims may focus on failure to warn about PML risk, failure to monitor for risk factors, or failure to discontinue Tysabri when PML was suspected. The adequacy of informed consent and adherence to the TOUCH program requirements are also relevant.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.